Oscar Health Inc FY2024 Financial Report: Revenue Up 58%, Net Loss Narrows to $27.1M

Executive Summary

Oscar Health Inc, traded on NYSE under the ticker OSCR, reported significant growth in revenue for FY2024, increasing by approximately 58% from the previous year, reaching $9.18 billion. Despite this revenue expansion, the company narrowed its net loss to $27.1 million compared to a loss of $270.6 million in FY2023, reflecting improved operational efficiency and strategic adjustments. The company’s balance sheet shows a strong cash position of $1.55 billion, with total assets of $4.84 billion, and a manageable long-term debt of $299.6 million. The cash flow statement indicates robust operating cash flow of $978 million, supporting ongoing investments and strategic initiatives. The company’s key ratios, including net margin and ROA, demonstrate a positive trend towards profitability, although net income remains in the red. Management continues to focus on expanding its member base, optimizing cost structures, and navigating regulatory and market risks to sustain long-term growth.

Key Metrics

Management Discussion and Analysis

Oscar Health’s FY2024 results highlight a robust revenue increase driven by member growth and premium expansion across its health insurance offerings. The company’s strategic exit from the Medicare Advantage market and the non-renewal of the Cigna+Oscar small group partnership have streamlined operations and reduced complexity. The significant revenue growth, coupled with a substantial reduction in net losses, underscores the effectiveness of cost management and operational efficiencies. The balance sheet remains strong with high liquidity, and cash flows from operations support ongoing investments in technology and member services. Regulatory and market risks persist, including potential changes in healthcare policies and competitive pressures, but the company’s diversified product portfolio and focus on technology-driven care position it well for sustainable growth.

Income Statement Analysis

In FY2024, Oscar reported total revenue of $9.18 billion, a 58% increase from $5.86 billion in FY2023, primarily due to higher premiums and member enrollment. Medical expenses increased proportionally, reflecting the growth in membership, totaling $7.33 billion. Operating expenses, including SG&A, rose to $1.76 billion, driven by member acquisition and administrative costs. The company’s earnings before taxes improved to $33.4 million from a loss of $267.3 million, with net income turning positive at $25.4 million compared to a net loss of $270.7 million in FY2023. Earnings per share (basic) improved to $0.11 from a loss of $1.22, indicating a significant turnaround. The gross margin remains under pressure due to high medical costs, but the narrowing net loss signals progress toward profitability.

Balance Sheet Analysis

As of December 31, 2024, Oscar’s total assets stood at $4.84 billion, up 34% from $3.60 billion at the end of FY2023. Cash and cash equivalents decreased slightly to $1.55 billion, but remain ample for operational needs. Premiums and receivables increased to $315.9 million, supporting revenue growth. The company’s liabilities totaled $3.82 billion, with benefits payable at $1.30 billion, reflecting the growth in insured members. Long-term debt remains stable at $299.6 million, and total stockholders’ equity increased to $1.02 billion, driven by retained earnings and capital raises. The balance sheet demonstrates a solid liquidity position and manageable leverage, providing flexibility for future expansion and investments.

Cash Flow Analysis

Operating cash flow for FY2024 was $978 million, a dramatic improvement from a negative $272 million in FY2023, driven by higher collections and better receivables management. Investing activities used $1.39 billion, mainly due to purchases of investments and capital expenditures on software and hardware. Financing activities generated $68.4 million, primarily from stock option exercises and joint venture contributions. The company’s free cash flow remains positive, supporting ongoing investments in technology, member acquisition, and strategic initiatives. Cash and cash equivalents at year-end totaled $1.55 billion, ensuring ample liquidity to meet operational and strategic needs.

Ratios & DuPont Analysis

Oscar’s net margin improved significantly to 0.28% from a negative margin in prior periods, reflecting the narrowing net loss. Return on assets (ROA) increased to 0.55%, indicating better asset utilization. Return on equity (ROE) improved to 2.5%, supported by higher net income and equity growth. Asset turnover ratio remains stable at approximately 1.9, demonstrating efficient use of assets in generating revenue. The equity multiplier is 4.76, indicating moderate leverage. Overall, the DuPont analysis suggests improved profitability and operational efficiency, though the company is still in transition toward sustained profitability.

Risk Factors

Key risks include regulatory changes affecting healthcare policies and reimbursement rates, market competition from other health insurers, operational risks related to technology and claims processing, and macroeconomic factors such as inflation and economic downturns. The company’s exposure to regulatory audits, potential legal proceedings, and market volatility could impact financial stability. Strategic focus on technology and diversified product offerings aims to mitigate some risks, but ongoing vigilance and adaptation are necessary.

Notes & Additional Commentary

FY2024 included strategic adjustments such as exiting Medicare Advantage and small group markets, which contributed to revenue growth and cost restructuring. Unusual items include accelerated stock-based compensation related to founders’ awards cancellation, impacting expenses. The company’s focus on technology-driven care and member engagement is expected to support long-term growth despite near-term challenges. No material adverse legal or regulatory outcomes are currently anticipated, but the risk remains.

Investment Implications

Oscar’s strong revenue growth and narrowing losses position it as a potential long-term growth story in the healthcare technology and insurance space. Short-term opportunities include capitalizing on increased member enrollment and technological efficiencies. Risks include regulatory uncertainties and competitive pressures. The company’s solid liquidity and strategic focus suggest a cautiously optimistic outlook, with potential for sustained profitability as operational efficiencies improve and market conditions stabilize.